000 04045nam a22005535i 4500
001 978-3-031-51292-6
003 DE-He213
005 20251030112050.0
007 cr nn 008mamaa
008 240521s2024 sz | s |||| 0|eng d
020 _a9783031512926
_9978-3-031-51292-6
024 7 _a10.1007/978-3-031-51292-6
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMJCL
_2thema
245 1 0 _aNeuroblastoma
_h[electronic resource] :
_bDiscoveries and Challenges /
_cedited by Shahab Asgharzadeh, Frank Westermann.
250 _a1st ed. 2024.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2024.
300 _aX, 219 p. 21 illus., 20 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aPediatric Oncology,
_x2191-0812
505 0 _aEpidemiology, Presentation, and Evaluation -- Pathology of Neuroblastoma -- Genetic Predisposition -- Part I: Evolving Concepts in Neuroblastoma Pathogenesis (Seed):Tumor Genomics: Copy Number Alterations -- Tumor Genomics: Epigenetics -- Tumor Genomics: Genomic Regulation -- Tumor Metabolism -- Part II: Evolving Concepts in Neuroblastoma Immunology and Tumor Microenvironment (Soil): Neuroblastoma Tumor Microenvironment - Adaptive and Innate Immunity -- Neuroblastoma Tumor Microenvironment – Non-Immune Cells and Exosomes -- Part III: Evolving Concepts in Neuroblastoma Precision Medicine: Targeting the Seed and the Soil: Advances in evaluating tumor burden -- Therapeutically Actionable Genetic Aberrations -- Re-engaging the Immune System: Future of Immunotherapy -- Future of Clinical Trials and Application of Precision Medicine -- Summary and the Next 10 Years. .
520 _aThis book provides a state-of-the-art review of the biology, treatment, and other critical aspects of neuroblastoma, reflecting the dramatic advances that have been achieved in understanding and management. Topics are arranged according to the book’s dominant themes of the “seed” (tumor genomics, epigenetics, metabolism, and stem cells) and the “soil” (tumor microenvironment, adaptive and innate immunity, and exosomes) and how both of these influences can serve as rich targets for intervention, whether by targeted molecular therapy or immunotherapy. Therapeutic strategies that are currently in use or under consideration for the future are discussed in detail, with the focus on precision medicine. Further individual chapters are devoted to the biology and genetics of relapsed/refractory neuroblastoma and emerging methods of evaluating tumor burden. Finally, in keeping with the, albeit modest, increase in cure rates in high-risk disease, immune and cellular therapies are reviewed. This coverage of what is becoming a not-so-enigmatic tumor will appeal to a broad readership including both experimental oncologists and clinicians who care for patients with neuroblastoma.
650 0 _aOncology.
_970760
650 0 _aPediatrics.
_964087
650 0 _aNeurology .
_966816
650 1 4 _aOncology.
_970760
650 2 4 _aPediatrics.
_964087
650 2 4 _aNeurology.
_966816
700 1 _aAsgharzadeh, Shahab.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_977123
700 1 _aWestermann, Frank.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_977124
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031512919
776 0 8 _iPrinted edition:
_z9783031512933
776 0 8 _iPrinted edition:
_z9783031512940
830 0 _aPediatric Oncology,
_x2191-0812
_977125
856 4 0 _uhttps://doi.org/10.1007/978-3-031-51292-6
912 _aZDB-2-SME
912 _aZDB-2-SXM
999 _c59990
_d59990